BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 23851982)

  • 21. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
    Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
    Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release.
    Ishii Y; Nhiayi MK; Tse E; Cheng J; Massimino M; Durden DL; Vigneri P; Wang JY
    PLoS One; 2015; 10(10):e0140585. PubMed ID: 26473951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
    San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
    Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells.
    Aranovich A; Liu Q; Collins T; Geng F; Dixit S; Leber B; Andrews DW
    Mol Cell; 2012 Mar; 45(6):754-63. PubMed ID: 22464442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence.
    Drullion C; Trégoat C; Lagarde V; Tan S; Gioia R; Priault M; Djavaheri-Mergny M; Brisson A; Auberger P; Mahon FX; Pasquet JM
    Cell Death Dis; 2012 Aug; 3(8):e373. PubMed ID: 22898871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.
    Shen Y; Shi X; Pan J
    PLoS One; 2013; 8(8):e73059. PubMed ID: 24009732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737.
    Shimada K; Tomita A; Minami Y; Abe A; Hind CK; Kiyoi H; Cragg MS; Naoe T
    Exp Hematol; 2012 Sep; 40(9):724-737.e2. PubMed ID: 22634393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.
    Estrada-Bernal A; Palanichamy K; Ray Chaudhury A; Van Brocklyn JR
    Neuro Oncol; 2012 Apr; 14(4):405-15. PubMed ID: 22351749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib.
    Augis V; Airiau K; Josselin M; Turcq B; Mahon FX; Belloc F
    PLoS One; 2013; 8(11):e78582. PubMed ID: 24223824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small-molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance.
    Song T; Guo Y; Xue Z; Guo Z; Wang Z; Lin D; Zhang H; Pan H; Zhang X; Yin F; Wang H; Uwituze LB; Zhang Z
    Leukemia; 2021 Oct; 35(10):2862-2874. PubMed ID: 34007045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells.
    Zhang L; Wang H; Ding K; Xu J
    Toxicol Lett; 2015 Jul; 236(1):43-59. PubMed ID: 25939952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 8‑bromo‑7‑methoxychrysin induces apoptosis by regulating Akt/FOXO3a pathway in cisplatin‑sensitive and resistant ovarian cancer cells.
    Ding Q; Chen Y; Zhang Q; Guo Y; Huang Z; Dai L; Cao S
    Mol Med Rep; 2015 Oct; 12(4):5100-8. PubMed ID: 26151347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia.
    Kuroda J; Shimura Y; Yamamoto-Sugitani M; Sasaki N; Taniwaki M
    Curr Cancer Drug Targets; 2013 Jan; 13(1):69-79. PubMed ID: 22414011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak.
    Willis SN; Fletcher JI; Kaufmann T; van Delft MF; Chen L; Czabotar PE; Ierino H; Lee EF; Fairlie WD; Bouillet P; Strasser A; Kluck RM; Adams JM; Huang DC
    Science; 2007 Feb; 315(5813):856-9. PubMed ID: 17289999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines.
    Belloc F; Moreau-Gaudry F; Uhalde M; Cazalis L; Jeanneteau M; Lacombe F; Praloran V; Mahon FX
    Cancer Biol Ther; 2007 Jun; 6(6):912-9. PubMed ID: 17538248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ribotoxic stress sensitizes glioblastoma cells to death receptor induced apoptosis: requirements for c-Jun NH2-terminal kinase and Bim.
    Xia S; Li Y; Rosen EM; Laterra J
    Mol Cancer Res; 2007 Aug; 5(8):783-92. PubMed ID: 17699104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.
    Sarosiek KA; Chi X; Bachman JA; Sims JJ; Montero J; Patel L; Flanagan A; Andrews DW; Sorger P; Letai A
    Mol Cell; 2013 Sep; 51(6):751-65. PubMed ID: 24074954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
    Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
    Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
    Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA
    J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.